Samsara Bio Capital, LLC Chinook Therapeutics, Inc. Transaction History

Samsara Bio Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $111 Million - $138 Million	5,161,888 New	5,161,888 $119 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $7.18 Million - $10.7 Million	570,000 Added 12.41%	5,161,888 $90.3 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $13 Million - $20.4 Million	1,215,000 Added 35.98%	4,591,888 $74.9 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $2.4 Million - $3.1 Million	208,500 Added 6.58%	3,376,888 $43.1 Million
Q4 2020 Feb 17, 2021	BUY	$11.9 - $20.91 $37.7 Million - $66.3 Million	3,168,388 New	3,168,388 $50.3 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.